Observed Signal · Oct 23, 2026 · Regulatory Approval · Source: PR Newswire: Advertising & Marketing · Impact: 2/5 · Sentiment: Positive

China Approves Harbour BioMed's Batoclimab for gMG

Executive Signal Summary

Harbour BioMed announced that China's NMPA has approved its Biologics License Application for batoclimab SC, a subcutaneous anti-FcRn therapy, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive. Approval was supported by a pivotal Phase 3 study in 27 Chinese centers showing significant improvements in primary and secondary endpoints. Batoclimab SC was generally well tolerated, with peripheral edema as the most common adverse event. Commercialization in Greater China will be conducted by NBP Pharma, a subsidiary of CSPC Pharmaceutical Group, under a license agreement, with Harbour BioMed receiving tiered royalties. Batoclimab was originally developed by HanAll Biopharma and licensed to Harbour BioMed in 2017.

Polaris7 AgentPolaris7 Strategic Assessment
High Confidence

This is a significant regulatory milestone for Harbour BioMed, but it is specific to the biopharmaceutical sector and not directly relevant to the AdTech/MarTech/AI industries. The event is a drug approval in China, which is outside the designated industry focus.

MARKET SIGNALS

Track Regulatory Approval Signals & Market Shifts

Polaris7 connects regulatory filings, primary sources, leadership changes, and M&A activity into structured intelligence. Set up your Polaris7 workspace to monitor relevant companies in your executive briefing.

  • Verified primary sources
  • Automated briefings
  • Instant watchlist setup

Key Takeaways & Evidence Grounding

  • China's NMPA approved batoclimab SC for treatment of generalized myasthenia gravis (gMG) in AChR antibody positive adult patients.
  • Approval based on Phase 3 study in 27 centers in China; primary endpoint achieved by 58.2% of batoclimab-treated patients vs 31.3% placebo (P=0.001).
  • Batoclimab SC showed significant improvements in secondary endpoints; most common adverse event was peripheral edema (38.8% vs 4.6% placebo).
  • Commercialization in Greater China will be conducted by NBP Pharma, a subsidiary of CSPC Pharmaceutical Group; Harbour BioMed receives tiered royalties.
  • Batoclimab was originally developed by HanAll Biopharma and licensed to Harbour BioMed in 2017.
Primary Source Grounding & Direct Attribution
Direct Origin Attribution
Primary Reporting: PR Newswire: Advertising & Marketing•Published: Oct 23, 2026
Original Coverage Title: “Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis”

Related Market Signals & Shifts

Recent verified developments and strategic activity across this market segment.

BiotechnologyOct 22, 2026

Kaigene Licenses KG013 to Celltrion in Global Deal

Kaigene, a U.S.-based biotechnology company, has entered into an exclusive worldwide licensing agreement with Celltrion for KG013, a next-generation anti-APRIL monoclonal antibody. Under the agreement, Kaigene grants Celltrion exclusive rights to develop and commercialize KG013 globally, while retaining an option for co-marketing in South Korea. The deal includes up to $580.5 million in upfront and milestone payments, plus royalties on net sales. KG013 is a half-life-extended, fully human antibody with femtomolar binding affinity, designed for long-acting subcutaneous administration, initially targeting IgA nephropathy (IgAN). The collaboration leverages Celltrion's global infrastructure for manufacturing, development, and commercialization of antibody therapeutics. This partnership aims to address significant unmet needs in IgA- and IgM-mediated autoimmune diseases, particularly in Asian populations.

Read assessment
BiotechNov 16, 2026

Fortvita Biologics Gets First Positive CHMP Opinion for Zybrivo

Fortvita Biologics, a member of the Innovent Group, announced its first positive opinion from the European Medicines Agency's CHMP. The opinion recommends marketing authorization for Zybrivo (sintilimab) in combination with chemotherapy for the first-line treatment of adults with advanced non-squamous non-small cell lung cancer. If approved by the European Commission, Zybrivo would be available across all 27 EU member states plus Iceland, Norway, and Liechtenstein. The recommendation is based on the Phase 3 ORIENT-11 study, which showed a 52% reduction in the hazard of disease progression or death and a 35% reduction in the hazard of death versus placebo plus chemotherapy. Fortvita is strengthening its capabilities for European market access. This is the first medicine in Fortvita's globalization strategy beyond China.

Read assessment
FundingOct 16, 2026

Microbiotica lands €42M Series C for microbiome therapy

Microbiotica, a British clinical-stage biopharma company, has announced the first close of a €42 million (£36 million) Series C financing round. The round was led by British Business Bank, with participation from Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest, and Seventure Partners, and included all existing Series B investors. The funds will be used to advance MB310, its precision microbiome therapy for ulcerative colitis, into Phase 2 clinical development, following positive Phase 1b results. Microbiotica's platform, spun out of the Wellcome Sanger Institute, identifies bacterial strains linked to favorable clinical outcomes. The company also partners with MSD, Cancer Research UK, and Genentech. This funding round is part of a broader trend of European biotech investments in microbiome and related therapies.

Read assessment

WATCHLIST & BRIEFINGS

Receive future signals for Regulatory Approval in your Watchlist briefing

Stay ahead of material M&A deals, leadership changes, account wins, and product rollouts. Polaris7 connects primary filings, company newsrooms, and trade reporting directly into your executive briefing.

  • Regular primary-source checks
  • Structured Watchlist briefings
  • Preserves current context